Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by Biotech777on Apr 22, 2014 10:06am
229 Views
Post# 22475962

RE:ATHERONOVA REVERSE STOCK SPLIT INTERESTING NOTE

RE:ATHERONOVA REVERSE STOCK SPLIT INTERESTING NOTE
Ive been following this one for quite a while now. Its basically a bile acid which acts as a detergent for lipids. It's interesting. They are doing their clinical work in Russia which isn't a shock as a couple years ago some Russian VC forms where throwing around a lot of money to small US biotechs. This certainly will be competitive to RVX if it works and is approved. My main issue with this company and this compound is that they put out fantastic pre-clinical data. Something like 95% plaque regression. However they stated nothing about the animal model, dosing, duration, how they measured regression, etc. You just can't put that kind of a number out without providing additional details and expect to betaken seriously. It reminds me of some of the stem cell plays that I follow.
Bullboard Posts